A Trial of the ALK Grass Tablet in Subjects With Hayfever

ALK-Abelló

Status and phase: Completed; Phase 3

Conditions: Allergy

Treatments: Biological: ALK Grass tablet

Study type: Interventional

Funder types: Industry

Identifiers

NCT00227279

GT-08

Details and patient eligibility

About

This trial is performed to assess the efficacy and safety of the ALK Grass tablet for treatment of grass pollen induced rhinoconjunctivitis (hayfever).

Enrollment: 634 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Eligibility Criteria:

• A history of grass pollen induced rhinoconjunctivitis
• Positive skin prick test to grass
• Positive specific IgE to grass

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

634 participants in 2 patient groups, including a placebo group

1

Experimental group

Treatment:

Biological: ALK Grass tablet

2

Placebo Comparator group

Treatment:

Biological: ALK Grass tablet